Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
759.12-
QQQ
707.880.47%
BTC/USD
75854.000.357%
DIA
522.140.17%
GLD
398.641.14%
TLT
80.85-

Viridian Therapeutics Inc (VRDN) Stock Price, Quote, News & History

VRDNNASDAQ
Trade with Public
Trade with Public
$21.83
-0.37-1.67%
At close: Sep 14, 5:00 PM EST
$21.83
-0.37-1.67%
Pre-Market: 5:57 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Viridian Therapeutics (VRDN) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
-
Close
$21.83
Volume / Avg.
142.00 / 1.88M
Day Range
- - -
52 Wk Range
13.18 - 34.29
Market Cap
$2.47B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
42
Short Interest
17.85%
Days to Cover
16.55

Recent Viridian Therapeutics, Inc. News

Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying

Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to survive another
Tim Melvin

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.
Vandana Singh

Stock Market Today: Nasdaq, Dow S&P 500 Futures Jump As Trump Admin Says US, Iran Will 'Stand Down' For Now— Verizon, HP, Universe Pharmaceuticals In Focus (UPDATED)

U.S. stock futures rose on Monday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, following Friday's mixed close.
Rishabh Mishra

Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket

Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announcing acquisition of Best Praise International for $10.75 million.
Avi Kapoor

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-333.34M
Investing Cash Flow (TTM)
-367.24M
Financing Cash Flow (TTM)
748.24M
Free Cash Flow (TTM)
-335.04M
Capital Expenditure (TTM)
-1.70M
Net Change in Cash (TTM)
47.66M

Analyst Trends and Forecast

4
1
Mar
5
Apr
3
May
6
Jun
2
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$1.83B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
29.65
PB Ratio (TTM)
4.38
Earnings Yield % (TTM)
-15.57%
Earnings Yield % (FWD)
-15.09%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$4.98

Company Debt

Total Debt
$242.16M
LT Debt
$242.16M
LT Debt Issuance (TTM)
$278.88M
LT Debt Repayment (TTM)
-
Total Cash
$164.99M
Debt to Equity
0.43
Issuance of Debt (TTM)
$224.18M
Repayment of Debt (TTM)
-

Key Statistics

Open
-
Close
$21.83
Volume / Avg.
142.00 / 1.88M
Day Range
- - -
52 Wk Range
13.18 - 34.29
Market Cap
$2.47B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
42
Short Interest
17.85%
Days to Cover
16.55

About

Sector
Health Care
Industry
Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligr...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Viridian Therapeutics (VRDN) stock?

A

You can purchase shares of Viridian Therapeutics (NASDAQ:VRDN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Viridian Therapeutics (VRDN) competitors?

Q

What is the forecast, or price target, for Viridian Therapeutics (VRDN) stock?

A

Viridian Therapeutics has a consensus price target of $37.27.

Q

What is the current price for Viridian Therapeutics (VRDN)?

A

The stock price for Viridian Therapeutics (NASDAQ: VRDN) is $21.83 last updated September 15, 2026 at 4:00 PM EDT.

Q

Does Viridian Therapeutics (VRDN) pay a dividend?

A

There are no upcoming dividends for Viridian Therapeutics.

Q

When is Viridian Therapeutics (NASDAQ:VRDN) reporting earnings?

A

Viridian Therapeutics does not have any upcoming earnings scheduled.

Q

Is Viridian Therapeutics (VRDN) going to split?

A

There is no upcoming split for Viridian Therapeutics.

Q

What sector and industry does Viridian Therapeutics (VRDN) operate in?

A

Viridian Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved